Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

The use of e-cigarettes among university students in Malaysia.

Puteh SEW, Manap RA, Hassan TM, Ahmad IS, Idris IB, Sham FM, Lin ABY, Soo CI, Mohamed RMP, Mokhtar AI, Zakaria H, Lee J, Nordin ASA, Ariaratnam S, Yusoff MZM.

Tob Induc Dis. 2018 Dec 10;16:57. doi: 10.18332/tid/99539. eCollection 2018.

2.

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.

Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF.

Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. doi: 10.1158/1078-0432.CCR-18-2728. Epub 2018 Dec 18.

PMID:
30563935
3.

Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.

Iwasa S, Yamamoto N, Shitara K, Tamura K, Matsubara N, Tajimi M, Lin AB, Asou H, Cai Z, Inoue K, Shibasaki Y, Saito K, Takai H, Doi T.

Cancer Sci. 2018 Oct;109(10):3216-3223. doi: 10.1111/cas.13750.

4.

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D.

Cancer Chemother Pharmacol. 2018 Sep;82(3):419. doi: 10.1007/s00280-018-3641-5.

PMID:
30014222
5.

Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom.

La EM, Smyth EN, Talbird SE, Li L, Kaye JA, Lin AB, Bowman L.

Eur J Cancer Care (Engl). 2018 Sep;27(5):e12862. doi: 10.1111/ecc.12862. Epub 2018 Jun 21.

6.

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D.

Cancer Chemother Pharmacol. 2018 Sep;82(3):407-418. doi: 10.1007/s00280-018-3623-7. Epub 2018 Jun 20. Erratum in: Cancer Chemother Pharmacol. 2018 Jul 16;:. Papadopoulous, Kyri [corrected to Papadopoulos, Kyriakos P] and Beeram, S Muralidhar [corrected to Beeram, Muralidhar].

7.

Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.

Hong DS, Moore K, Patel M, Grant SC, Burris HA 3rd, William WN Jr, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell J.

Clin Cancer Res. 2018 Jul 15;24(14):3263-3272. doi: 10.1158/1078-0432.CCR-17-3347. Epub 2018 Apr 11.

8.

Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair.

Lin AB, McNeely SC, Beckmann RP.

Clin Cancer Res. 2017 Jul 1;23(13):3232-3240. doi: 10.1158/1078-0432.CCR-16-0083. Epub 2017 Mar 22. Review.

9.

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.

Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang DZ, Kim G, Stella P, Richel D, Szcylik C, Cascinu S, Frassineti GL, Ciuleanu T, Hurt K, Hynes S, Lin J, Lin AB, Von Hoff D, Calvo E.

BMC Cancer. 2017 Feb 15;17(1):137. doi: 10.1186/s12885-017-3131-x.

10.

UNUSUAL SEROUS RETINAL DETACHMENT IN A PATIENT WITH WALDENSTROM MACROGLOBULINEMIA: A CASE REPORT.

Lin AB, Sheyman AT, Jampol LM.

Retin Cases Brief Rep. 2019 Winter;13(1):1-4. doi: 10.1097/ICB.0000000000000540.

PMID:
28106626
11.

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

Infante JR, Patnaik A, Verschraegen CF, Olszanski AJ, Shaheen M, Burris HA, Tolcher AW, Papadopoulos KP, Beeram M, Hynes SM, Leohr J, Lin AB, Li LQ, McGlothlin A, Farrington DL, Westin EH, Cohen RB.

Cancer Chemother Pharmacol. 2017 Feb;79(2):315-326. doi: 10.1007/s00280-016-3205-5. Epub 2017 Jan 17.

PMID:
28097385
12.

Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes.

Tsai IF, Kuo CP, Lin AB, Chien MN, Ho HT, Wei TY, Wu CL, Lu YT.

Respirology. 2017 Apr;22(3):559-566. doi: 10.1111/resp.12948. Epub 2016 Nov 23.

PMID:
27879023
13.

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.

Scagliotti G, Kang JH, Smith D, Rosenberg R, Park K, Kim SW, Su WC, Boyd TE, Richards DA, Novello S, Hynes SM, Myrand SP, Lin J, Smyth EN, Wijayawardana S, Lin AB, Pinder-Schenck M.

Invest New Drugs. 2016 Oct;34(5):625-35. doi: 10.1007/s10637-016-0368-1. Epub 2016 Jun 27.

PMID:
27350064
14.

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J.

J Clin Oncol. 2016 May 20;34(15):1764-71. doi: 10.1200/JCO.2015.64.5788. Epub 2016 Apr 4. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):356.

15.

Analysis of the immune response of human dendritic cells to Mycobacterium tuberculosis by quantitative proteomics.

Kuo CP, Chang KS, Hsu JL, Tsai IF, Lin AB, Wei TY, Wu CL, Lu YT.

Proteome Sci. 2016 Mar 8;14:5. doi: 10.1186/s12953-016-0095-8. eCollection 2016.

16.

Bicyclol attenuates tetracycline-induced fatty liver associated with inhibition of hepatic ER stress and apoptosis in mice.

Yao XM, Li Y, Li HW, Cheng XY, Lin AB, Qu JG.

Can J Physiol Pharmacol. 2016 Jan;94(1):1-8. doi: 10.1139/cjpp-2015-0074. Epub 2015 Sep 22.

PMID:
26640164
17.

Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.

Doi T, Yoshino T, Shitara K, Matsubara N, Fuse N, Naito Y, Uenaka K, Nakamura T, Hynes SM, Lin AB.

Anticancer Drugs. 2015 Nov;26(10):1043-53. doi: 10.1097/CAD.0000000000000278.

PMID:
26288133
18.

Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates.

Chou DH, Webber MJ, Tang BC, Lin AB, Thapa LS, Deng D, Truong JV, Cortinas AB, Langer R, Anderson DG.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2401-6. doi: 10.1073/pnas.1424684112. Epub 2015 Feb 9.

19.

Medical therapy for glaucoma: what to add after a prostaglandin analogs?

Tanna AP, Lin AB.

Curr Opin Ophthalmol. 2015 Mar;26(2):116-20. doi: 10.1097/ICU.0000000000000134. Review.

PMID:
25594765
20.

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.

Calvo E, Chen VJ, Marshall M, Ohnmacht U, Hynes SM, Kumm E, Diaz HB, Barnard D, Merzoug FF, Huber L, Kays L, Iversen P, Calles A, Voss B, Lin AB, Dickgreber N, Wehler T, Sebastian M.

Invest New Drugs. 2014 Oct;32(5):955-68. doi: 10.1007/s10637-014-0114-5. Epub 2014 Jun 20.

PMID:
24942404
21.

Mesenchymal stem cells in regenerative medicine for musculoskeletal diseases: bench, bedside, and industry.

Wei CC, Lin AB, Hung SC.

Cell Transplant. 2014;23(4-5):505-12. doi: 10.3727/096368914X678328. Review.

PMID:
24816447
22.

A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models.

Yin T, Lallena MJ, Kreklau EL, Fales KR, Carballares S, Torrres R, Wishart GN, Ajamie RT, Cronier DM, Iversen PW, Meier TI, Foreman RT, Zeckner D, Sissons SE, Halstead BW, Lin AB, Donoho GP, Qian Y, Li S, Wu S, Aggarwal A, Ye XS, Starling JJ, Gaynor RB, de Dios A, Du J.

Mol Cancer Ther. 2014 Jun;13(6):1442-56. doi: 10.1158/1535-7163.MCT-13-0849. Epub 2014 Mar 31.

23.

The top PDA resources for family physicians.

Lin AB.

Fam Pract Manag. 2006 Jul-Aug;13(7):44-6. No abstract available. Erratum in: Fam Pract Manag. 2006 Sep;13(8):24.

Supplemental Content

Support Center